Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

Peter Marks, MD, PhD, director of FDA's Center for Biologics Evaluation and Research (CBER), strongly refuted claims made by Joseph Ladapo, MD, PhD, that the vaccines may be contaminated with DNA ...

A former Deputy National Chairman of the Peoples Democratic Party (PDP), Chief Olabode George, has criticized the trio of ...

The black-and-white thinking in our politics brings to mind a skill that the state of Texas requires me to teach my college ...

Pope Leo XIV is marking a feast day as the Vatican launches a new campaign to boost donations from the faithful. Leo ...

Pope Leo XIV on Sunday celebrated a special feast day traditionally used by the Catholic Church to drum up donations from the ...

The infusion of new leaders and members into the African Democratic Congress, marked by the emergence of David Mark and Rauf ...

Princess Andre celebrated turning 18th with a glamorous photoshoot shared on Sunday to mark the special milestone.The budding ...

The abrupt departure of Peter Marks as the director of the FDA's Centre for Biologics Evaluation and Research (CBER), citing irreconcilable differences with new Health and Human Services Secretary ...

Gene editing stocks were largely steady in the premarket on Friday after the FDA’s CBER unit faced another abrupt leadership transition. Read more here.

Leo celebrated Mass in St. Peter’s Basilica, marking the Feast of Saints Peter and Paul, during which he gave the pallium woolen stole to 54 new archbishops.

Dr Peter Marks, director of the FDA Center for Biologics Evaluation and Research told a packed house in San Francisco for JPM that FDA wants to support gene therapies in 2024.